American Heart Association (AHA) Scientific Sessions 2025

The novel glycoprotein IIb/IIIa inhibitor zalunfiban, administered at first medical contact in patients having ST-elevation myocardial infarction (STEMI), enhances patency of the infarct-related artery upon arrival in the catheterisation laboratory, in the phase III CeleBrate trial. It also improves 30-day cardiovascular (CV) outcomes, without increasing major bleeding.

Long-term supplementation (≥12 months) with melatonin is associated with a higher risk of incident heart failure (HF) diagnosis, hospitalization for HF (HHF), and all-cause mortality in individuals with chronic insomnia in a large retrospective review of electronic health records (EHRs) presented at AHA 2025.

A systemic review presented at AHA 2025 demonstrates the potential of etripamil nasal spray as a patient-administered therapy for paroxysmal supraventricular tachycardia (PSVT), which may reduce reliance on emergency care.

Patients with non-small cell lung cancer (NSCLC) treated with osimertinib have a higher risk of QT prolongation, reduced ejection fraction, and high-grade cardiac failure than those who received placebo or other standard therapies, reports a study.

Treatment with tirzepatide 15 mg/week results in a 33-percent reduction in the risk of major adverse cardiovascular events (MACE), results of a meta-analysis have shown. Moreover, its efficacy is consistent across individuals with or without obesity.